



## Cell and Gene Therapy Medications Billing Guidance for Priority Partners Providers

**Effective Date:** Feb. 1, 2026

**Health Plans Affected:** Priority Partners

**Type of Change:** Billing Guidance

### Explanation of Change:

Please use a **UB04 claim** for Priority Partners patients for the Cell and Gene Therapy (CGT) medications CASGEVY or LYFGENIA, related to the CGT Access Model (Model).

- The Model requires the reimbursement of the approved medication to be at no less than actual acquisition cost.
- Priority Partners providers may submit for the medication and infusion inpatient stay on the same claim.
- An additional condition of payment for the CGT Model medications ensures that the authorized/qualified treatment center is a member of the Center for International Blood & Marrow Transplant Research (CIBMTR) registry and the provider participates in the CMS-directed study for the CGT Model gene therapies.
  - More information on CIBMTR centers is available [here](#).
  - **Note:** Both Children's National Medical Center and University of Maryland Medical Center are CIBMTR participating centers.
- Providers may not use 340B discounts on any CGT Model Medications.
- At this time, Maryland Medicaid Fee-for-Service and Priority Partners are not allowing any specialty pharmacies to submit claims for these medications.